Publication | Closed Access
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study
57
Citations
16
References
2022
Year
Our real-life study confirmed the efficacy and safety of guselkumab in daily clinical practice suggesting it as a valuable weapon also in psoriasis patients who previously failed anti-IL17 treatments.
| Year | Citations | |
|---|---|---|
Page 1
Page 1